A Blood Test for Liver Scarring: How a Collagen Peptide Tracks Fibrosis Without Biopsy
Blood levels of a collagen fragment (procollagen III peptide) closely tracked the severity of liver scarring in schistosomiasis patients, offering a non-invasive alternative to biopsy.
Quick Facts
What This Study Found
Serum levels of the N-terminal procollagen type III peptide (PIIINP) showed a high correlation with the degree of liver fibrosis in patients with schistosomiasis. This peptide biomarker tracked with histopathological findings from liver biopsies, suggesting it could serve as a non-invasive marker to monitor the dynamic process of liver scarring — something a one-time biopsy cannot capture.
Key Numbers
High correlation between serum PIIINP and histological fibrosis grade · Liver function tests correlated with histopathological diagnosis
How They Did This
Researchers measured serum concentrations of procollagen type III peptide and standard liver function tests in patients with schistosomiasis mansoni. These results were compared against histopathological diagnosis from liver biopsies to determine how well the blood marker correlated with the actual degree of liver fibrosis.
Why This Research Matters
Liver biopsy is painful, invasive, and only provides a snapshot of damage at one moment. A blood-based peptide biomarker that reflects ongoing fibrosis activity could allow doctors to track disease progression over time without repeated biopsies. This early study helped establish PIIINP as a clinically useful marker, a concept that has since expanded to many liver diseases beyond schistosomiasis.
The Bigger Picture
This 1987 study was part of the early wave of research establishing peptide-based biomarkers for liver disease. PIIINP has since become one of the most widely validated non-invasive fibrosis markers and is now included in composite scores like the Enhanced Liver Fibrosis (ELF) test used clinically for conditions ranging from hepatitis to NAFLD/MASH. The concept of using collagen fragments as disease biomarkers has expanded far beyond the liver.
What This Study Doesn't Tell Us
The abstract provides limited quantitative data — no specific correlation coefficients, sample sizes, or sensitivity/specificity values are reported. The study focused exclusively on schistosomal liver fibrosis, so generalizability to other causes of liver fibrosis is not established. Being from 1987, the assay technology for measuring PIIINP has since improved significantly.
Questions This Raises
- ?How does PIIINP compare to modern non-invasive fibrosis markers like FibroScan or the ELF score?
- ?Can serial PIIINP measurements predict which patients will progress to cirrhosis versus stabilize?
- ?Is this biomarker useful for monitoring treatment response in patients receiving anti-fibrotic therapies?
Trust & Context
- Key Stat:
- High correlation Serum procollagen type III peptide levels closely matched the histological degree of liver fibrosis, validating a blood-based alternative to invasive liver biopsy
- Evidence Grade:
- This is an observational clinical study with histopathological confirmation. While it demonstrates a clear correlation, the abstract lacks specific statistical metrics. The single-disease focus and older methodology are limitations, though the core finding has been extensively validated by subsequent research.
- Study Age:
- Published in 1987, this is a foundational early study in peptide biomarker research. While the assay technology has improved dramatically since then, the core concept — using PIIINP to track liver fibrosis — remains clinically relevant and is now part of validated diagnostic panels.
- Original Title:
- Serum concentration of N-terminal procollagen peptide of collagen type III in schistosomal liver fibrosis.
- Published In:
- Experimental and molecular pathology, 46(3), 383-90 (1987)
- Authors:
- el-Mohandes, M, Hassanein, H, el-Badrawy, N, Voss, B, Gerlach, U
- Database ID:
- RPEP-00042
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What is procollagen type III peptide and why does it appear in blood during liver disease?
When your liver is forming scar tissue, it produces large amounts of type III collagen. During this process, a fragment called the N-terminal procollagen III peptide (PIIINP) gets clipped off and enters the bloodstream. Higher blood levels indicate more active scarring, making it a useful marker for tracking liver fibrosis without needing a biopsy.
Is this blood test used today?
Yes — PIIINP is now part of the Enhanced Liver Fibrosis (ELF) test, a validated clinical panel that helps doctors assess liver scarring in conditions like fatty liver disease, hepatitis, and alcohol-related liver disease. This 1987 study was one of the early papers that established the scientific basis for this now-standard approach.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00042APA
el-Mohandes, M; Hassanein, H; el-Badrawy, N; Voss, B; Gerlach, U. (1987). Serum concentration of N-terminal procollagen peptide of collagen type III in schistosomal liver fibrosis.. Experimental and molecular pathology, 46(3), 383-90.
MLA
el-Mohandes, M, et al. "Serum concentration of N-terminal procollagen peptide of collagen type III in schistosomal liver fibrosis.." Experimental and molecular pathology, 1987.
RethinkPeptides
RethinkPeptides Research Database. "Serum concentration of N-terminal procollagen peptide of col..." RPEP-00042. Retrieved from https://rethinkpeptides.com/research/el-mohandes-1987-serum-concentration-of-nterminal
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.